ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Sanofi and Evotec are in talks to create an infectious disease research center in Lyon, France, that is open to outside groups. Under the proposed deal, Sanofi’s early-stage infectious disease portfolio and 100 researchers will be folded into Evotec, which will get nearly $75 million and other “significant, long-term funding” from Sanofi. The French firm is keeping its vaccine activities and retains an option to license back certain anti-infective drugs. In 2015, Evotec took over Sanofi’s small-molecule drug development site in Toulouse, France, taking on more than 200 chemists. Sanofi paid the contract research firm $275 million over five years.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter